The current therapeutic approach to treat non dystrophic myotonias, regardless of the underlying channel defect, be it ClC-1 or Nav1.4, is based on available sodium channel blockers that work by lowering sarcolemmal excitability. Here, SCN4A is linked to Myotonia.